Antiretroviral Guidelines
Refer to BHIVA-guidelines-on-antiretroviral-treatment-for-adults-living-with-HIV-1-2022.pdf for full guidelines for adults
Refer to British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update) (bhiva.org) for pregnancy guidelines
Drug interactions
Multiple interactions exist with antiretroviral drugs. Refer to www.hiv-druginteractions.org or contact HIV specialist pharmacists for advice.
OUHFT Antiretroviral Formulary
|
|
NRTIs |
NNRTIs |
Integrase Inhibitors |
Protease Inhibitors |
Other |
Combination tablets |
|
Formulary drug: No restriction on use |
Abacavir1
Lamivudine
Tenofovir disoproxil2
Emtricitabine |
Rilpivirine
Doravirine
|
Dolutegravir3
Raltegravir |
Boosted Darunavir (as a once daily regime – no PI resistance)
Ritonavir (as pharmacokinetic booster of Darunavir) |
Cobicistat4 |
Abacavir/lamivudine Tenofovir disoproxil/emtricitabine2 Delstrigo (tenofovir disoproxil/lamivudine/doravirine)2 Triumeq (abacavir/lamivudine/dolutegravir)1,3 Tenofovir disoproxil/emtricitabine/efavirenz2 Dovato (lamivudine/dolutegravir)3 Juluca (dolutegravir/rilpivirine)3 |
|
Formulary drug: For continuation only |
Zidovudine
|
Efavirenz Nevirapine Etravirine |
|
Atazanavir boosted with ritonavir |
|
Kaletra (lopinavir/ritonavir)
|
|
Formulary: Consultant initiation only |
|
|
|
Boosted Darunavir (as a twice daily regime for resistant virus) |
Maraviroc |
|
|
Restricted: Must meet NHSE commissioning criteria and MDT discussion |
Tenofovir alafenamide (in combination) |
|
Elvitegravir (as Stribild)
Bictegravir (as Biktarvy)
|
|
Stribild (tenofovir disoproxil/emtricitabine/ elvitegravir/cobicistat)2, 4 Biktarvy (tenofovir alafenamide/emtricitabine/bictegravir) Descovy 10/200mg (tenofovir alafenamide/emtricitabine) Descovy 25/200mg (tenofovir alafenamide/emtricitabine) Genvoya (tenofovir alafenamide/emtricitabine/ elvitegravir/cobicistat)4 Odefsey (tenofovir alafenamide/emtricitabine/ rilpivirine) |
|
|
Restricted: Must meet NHSE commissioning criteria, MDT discussion and Blueteq
|
|
Rilpivirine IM
|
Cabotegravir PO/IM |
|
|
Symtuza (tenofovir alafenamide/emtricitabine/ darunavir/cobicistat)4
|
|
NHSE commissioning: For continuation only |
|
|
|
|
|
Rezolsta (darunavir/cobicistat)4 Eviplera (tenofovir disoproxil/emtrictabine/rilpivirine)2 Evotaz (atazanavir/cobicistat)4 |
1 After HLA B57*01 test. Caution if significant cardiovascular risk factors.
2 Avoid in renal impairment.
3 Avoid in less than 6 weeks gestation.
4 Avoid in pregnancy.